Table 4. Univariate regression analysis of protein analytes versus lung function parameters in COPD subjects with and without metabolic syndrome.
With Metabolic Syndrome (n = 55) | Without Metabolic Syndrome (n = 47) | ||||
Lung Function Parameter/Analyte | Spearman Correlation | p (FDR) | Spearman Correlation | p (FDR) | Interaction p |
FEV1/FVC ratio | |||||
MPO | −0.15 | 0.96 | −0.61 | 0.023 | 0.09 |
NGAL | −0.35 | 0.25 | −0.54 | 0.023 | 0.65 |
DLCO % predicted | |||||
Fibrinogen | −0.25 | 0.47 | −0.52 | 0.005 | 0.08 |
HB-EGF | −0.44 | 0.13 | −0.45 | 0.027 | 0.55 |
MCP-4 | −0.52 | 0.03 | −0.28 | 0.342 | 0.29 |
Significance (p values) and effect sizes (spearman correlation) are listed for biomarker associations with lung function parameters. Interaction p values indicate significance of differences in biomarker associations with lung function parameters, between metabolic syndrome and non- metabolic syndrome groups.